Clara cell protein in nasal lavage fluid and nasal nitric oxide - biomarkers with anti-inflammatory properties in allergic rhinitis by Kristina Irander et al.
RESEARCH Open Access
Clara cell protein in nasal lavage fluid and nasal
nitric oxide - biomarkers with anti-inflammatory
properties in allergic rhinitis
Kristina Irander1, Jörgen P Palm2, Magnus P Borres3,4 and Bijar Ghafouri5,6*
Abstract
Background: Clara cell protein (CC16) is ascribed a protective and anti-inflammatory role in airway inflammation.
Lower levels have been observed in asthmatic subjects as well as in subjects with intermittent allergic rhinitis than
in healthy controls. Nasal nitric oxide (nNO) is present in high concentrations in the upper airways, and considered
a biomarker with beneficial effects, due to inhibition of bacteria and viruses along with stimulation of ciliary
motility. The aim of this study was to evaluate the presumed anti-inflammatory effects of nasal CC16 and nNO in
subjects with allergic rhinitis.
Methods: The levels of CC16 in nasal lavage fluids, achieved from subjects with persistent allergic rhinitis (n = 13),
intermittent allergic rhinitis in an allergen free interval (n = 5) and healthy controls (n = 7), were analyzed by
Western blot. The levels of nNO were measured by the subtraction method using NIOX®. The occurrences of
effector cells in allergic inflammation, i.e. metachromatic cells (MC, mast cells and basophiles) and eosinophils (Eos)
were analyzed by light microscopy in samples achieved by nasal brushing.
Results: The levels of CC16 correlated with nNO levels (r2 = 0.37; p = 0.02) in allergic subjects.
The levels of both biomarkers showed inverse relationships with MC occurrence, as higher levels of CC16 (p = 0.03)
and nNO (p = 0.05) were found in allergic subjects with no demonstrable MC compared to the levels in subjects
with demonstrable MC. Similar relationships, but not reaching significance, were observed between the CC16 and
nNO levels and Eos occurrence. The levels of CC16 and nNO did not differ between the allergic and the control
groups.
Conclusions: The correlation between nasal CC16 and nNO levels in patients with allergic rhinitis, along with an
inverse relationship between their levels and the occurrences of MC in allergic inflammation, may indicate that
both biomarkers have anti-inflammatory effects by suppression of cell recruitment. The mechanisms behind these
observations warrant further analyses.
Keywords: CC16, nasal nitric oxide, allergic rhinitis, anti-inflammatory effects, metachromatic cells, mast cells, baso-
phils, eosinophils, nasal lavage fluid, upper airways
Background
Clara cell protein (CC16, identical to CC10 and utero-
globin) is a biomarker of high interest in airway diseases.
The protein, initially described in the epithelium of the
tracheobronchial tree as a secretory product from non-
ciliated Clara cells, diffuses passively from the respira-
tory tract into serum and is excreted via the urinary
tract [1]. CC16 is ascribed a protective role against oxi-
dative stress and inflammation in the respiratory tract
[2]. Due to a particular vulnerability of Clara cells to
lung toxicants CC16 has also been evaluated as a useful
biomarker of respiratory epithelial damage in acute and
chronic exposures to airway irritants [1-3]. Most studies
have focused on the lower airways with results based on
CC16 levels in serum, sputum and bronchoalveolar
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lavage fluid. In asthmatic children and adults lower
levels have been found compared to healthy controls [3].
Although CC16 also has been demonstrated in nasal
lavage fluid [NLF] [4], only a few studies on nasal levels
have been reported. Thus, the CC16 levels in NLF
related to exposures to air pollutions have been ana-
lyzed, with decreased levels found in a group of epoxy
workers with chronic exposure to an irritating chemical
[5], in contrast to increased levels after acute exposure
to hot humid ozone-polluted environment in combina-
tion with physical exercise [6]. In intermittent allergic
rhinitis due to pollen allergy the levels were lower in
patients compared to controls during the pollen season
[7,8], and an inverse relation between nasal CC16 levels
and symptoms and signs of rhinitis were observed after
allergen-challenge [9]. No study analyzing the nasal
CC16 levels in persistent allergic rhinitis has up to now
been found.
The aims of this report were, besides analyses of nasal
CC16 levels in subjects with persistent allergic rhinitis
and subjects with intermittent allergic rhinitis during a
symptom-free interval, to evaluate the presumed protec-
tive role of nasal CC16 in allergic inflammation. The
CC16 levels were therefore related to nasal nitric oxide
(nNO) that is present in high concentrations in the
upper airways, and considered a biomarker with benefi-
cial effects, due to inhibition of bacteria and viruses
along with stimulation of ciliary motility [10]. Further-
more, the analyses included the relations between the
levels of both CC16 and nNO and the occurrence of
nasal metachromatic cells (MC, mast cells and baso-
phils) and eosinophils (Eos), i.e. the major effector cells
in IgE-mediated allergic inflammation.
Methods
Subjects
The subjects were included in a cohort during infancy
and followed regarding development of allergy symptoms
[11-13]. At the 18-year follow-up we took the opportu-
nity to analyze the expression of different biomarkers in
the upper airways. The examinations were performed out
of pollen season and the subjects had to be free from air-
way infections for at least 10 days prior to the examina-
tion, thus with all subjects being in a period in optimal
good health. The diagnoses of upper and lower airway
allergy and atopic dermatitis were based on clinical his-
tories of allergy symptoms and careful clinical examina-
tions as previously described in detail [13].
Allergic rhinitis subjects (n = 18), with or without
bronchial or skin symptoms were included in this
report, while individuals suffering from dermatitis with-
out airway problems or presenting inconclusive symp-
toms were excluded. Subjects reporting use of nasal
decongestants, local or systemic steroids or smoking
habits, factors with known or suspected effects on the
CC16 and nNO levels, were too low in number to be
evaluated separately and therefore not included. All of
the rhinitis subjects were sensitized to one or more
allergens according to a skin prick test using ALK
extracts (ALK, Sweden AB) with perennial allergens
(horse, cat, dog, D. pteronyssinus, D. farinae, Alternaria,
Cladosporium) and pollen allergens (birch, timothy,
mugwort). The rhinitis subjects were separated into a
persistent allergy sub-group (n = 13) due to sensitization
to perennial allergens regardless of any concurring posi-
tive pollen tests, and an intermittent allergy sub-group
(n = 5), sensitized to pollens only and thus not exposed
to any offending allergens for at least three months.
Healthy, non-sensitized subjects served as a control
group (n = 7).
Current symptoms on the day of examination, includ-
ing four rhinitis symptoms (itching, sneezing, secretion
and obstruction) and four bronchial symptoms (cough,
mucous production, wheezing and dyspnea) were scored
from 0 (no symptoms) to 10 (disabling symptoms) on
visual analogue scales.
Nasal lavage samples
Nasal lavage was performed using saline pre-warmed to
37°C. The subject kept the head bent forward with the
face held horizontally, while the left nasal cavity was
filled with saline, using a 10 ml syringe connected to the
nostril via a short tube and a nasal olive. After five min-
utes approximately five ml of the saline could be recov-
ered by aspiration. The samples were centrifuged to
remove cellular debris and aliquots of the supernatants
were stored at - 20°C in eppendorff tubes until analysis.
Total protein concentrations were determined with Bio-
Rad protein assays according to Bradford [14].
Western blot analysis of CC16 levels
Proteins from NLF were separated using SDS-PAGE,
with a gradient gel range T: 5-20% and C: 1.5% and a
stacking gel with T: 5% and C: 5% on Mini-Protean II
electrophoresis cell from Bio-Rad Laboratories. Samples,
40 μg of protein, were mixed 1:1 with cocktail (10% w/v
SDS, 150 mM DTT, 1% w/v bromphenol blue, 0.5 mM
Tris-HCl pH 6.8, glycerol). The samples were boiled for
three minutes, according to standard procedures, before
loaded in the wells on the SDS-PAGE and run in elec-
trode buffer (0.16% w/v Tris, 0.72% w/v glycine, 0.05%
w/v SDS). The SDS-PAGE was run for approximately 30
minutes in 100 V, 60 mA and then elevated to 200 V
until finished.
SDS-PAGE gels were blotted on Immun-Blot PVDF
Membrane using Mini Trans-Blot Electrophoretic
Transfer Cell (Bio-Rad Laboratories). Membranes were
blocked in Tris-buffered saline (40 mM Tris-HCl, 500
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mM NaCl, pH 7.5) with 5% non-fat dried milk over
night. Membranes were washed with Tween-20 Tris-
buffered saline (TTBS: 40 mM Tris-HCl, 500 mM NaCl,
0.05% Tween-20) and incubated with primary antibody
against CC16 (Biovendor RD181022220) in TTBS with
2% non-fat dried milk over night. The membranes were
washed with TTBS and followed by incubation with
HRP-conjugated secondary antibody (anti-goat/sheep
IgG, SIGMA, MI, USA) for 1 h. The latter wash proce-
dure was repeated once pursued by detection of anti-
gen/antibody conjugate with ECL (GE Healthcare) and
developed on X-ray film. The X-ray films were analyzed
as digitized images using a CCD (charged-coupled
device) camera (1340 × 1040 pixels) in combination
with a computerized imaging 12-bit system. The amount
of protein in a band was assessed as optical density
(OD).
Measurements of nitric oxide from the upper and lower
airways
Measurements of nitric oxide (NO) followed the ATS
recommendations [15] using NIOX® (Aerocrine AB,
Sweden) at a flow rate of 3 l/min. The values of NO
from the upper airways (nNO) were calculated accord-
ing to the subtraction method [16], regarded to be the
best validated method where a transnasal flow is used
[15]. Briefly, when measuring nasally exhaled NO, a
tight-fitting nasal mask was adapted to the mouthpiece
used for oral exhalations, and the mean of three record-
ings was calculated. Before measuring the orally exhaled
NO (eNO), the subject performed a mouthwash with 20
ml of sodium bicarbonate solution (10%) for 1 minute,
in order to avoid the non-airway contribution of NO
from saliva in the oropharyngeal tract [17]. The mean
from three immediately performed recordings was cal-
culated. This eNO mean value was subtracted from the
mean value of nasally exhaled NO, in the calculation of
nNO. Thus, nNO as calculated using the subtraction
method represents the supra-velar airway contribution
to nasally exhaled NO.
Cytospin preparations of nasal mucosal cells
Mucosal cells were harvested from the right nasal cavity
by a gentle nasal brushing using a 5.5 mm diameter
nylon brush (Doft AB, Östhammar, Sweden). The brush
was immediately placed in a tube containing physiologi-
cal saline and twirled for 3-5 seconds. After cytocentri-
fugation onto glass slides, the materials were air-dried
and fixated in 95% ethanol or methanol for later stain-
ing with toluidine blue for visualization of MC and
Wright’s stain for visualization of Eos, respectively.
Blinded analysis of the cells on coded slides was per-
formed by light microscopy (magnification × 250).
Occurrence of one or more of the cells was regarded as
a positive result (MCpos and Eospos, respectively), and
absence of cells as a negative result (MCneg and Eosneg,
respectively), provided the density of epithelial cells
were > 25 cells per visual field.
Statistical analyses
In general, statistics were analyzed by non-parametric
methods, using the Graph Pad Prism software program.
Mann-Whitney U Test was used in calculations of dif-
ferences between two groups. Results are presented as
mean values ± 1 standard deviation. Spearman Rank
Correlation was used in evaluating correlations. A p-
value of < 0.05 was regarded as significant.
Ethics
The study was performed according to the Helsinki
Declaration and approved by the Ethical committee at
the University Hospital in Linköping, Sweden (03694). A




The combined scores of the four nasal symptoms and
the four bronchial symptoms are presented in Table 1.
The symptoms were mild with only slightly higher score
values in the persistent allergy sub-group with current
allergen exposure.
Protein concentrations in nasal lavages
The concentrations of the total amount of proteins in
NLF were 350 ± 340 μg/ml (persistent allergy sub-
group), 440 ± 260 μg/ml (intermittent allergy sub-group)
and 320 ± 310 μg/ml (control group). No significant sta-
tistical differences between the groups were found.
Levels of CC16, nNO and eNO and occurrences of MC and
Eos in relation to allergic rhinitis
The levels of CC16 were slightly, but not significantly,
higher in the allergy sub-groups compared to the con-
trol group (Table 1, Figure 1).
The nNO levels were slightly lower in the two allergy
sub-groups compared to the control group, but with no
significant differences. In contrast, eNO was higher in
the sub-group with persistent allergy compared to the
sub-group with intermittent allergy (p = 0.06) and to
the control group (p < 0.05) (Table 1).
Analyses of cell occurrences showed positive results
(MCpos and Eospos) in subjects from the two allergy
sub-groups, but some of the members in both sub-
groups had negative results (MCneg and Eosneg). In the
control group MCs were not found in any subjects,
whereas Eos were found in two of them (one slide was
failed) (Table 1).
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Thus, the sub-group with persistent rhinitis was dis-
cerned from the sub-group with intermittent rhinitis
and the healthy control group only by eNO, but not by
any of the upper airway markers.
Correlation between CC16 and nNO levels
A significant positive correlation was found between the
CC16 and the nNO levels in the combined allergic rhi-
nitis sub-group (n = 18; r2 = 0.37; p = 0.02; Figure 2).
Levels of CC16 and nNO in relation to occurrences of MC
and Eos
The levels of both CC16 and nNO in the combined sub-
group of allergic rhinitis were significantly higher in
subjects with MCneg results compared to the levels in
subjects with MCpos results (21 ± 19 OD vs 10 ± 5 OD;
p = 0.03 and 83 ± 32 ppb vs 53 ± 25 ppb; p = 0.05,
respectively; Figure 3A-B).
In subjects with Eosneg higher levels of CC16 (20 ± 12
OD vs 13 ± 7 OD) and nNO (80 ± 36 ppb vs 61 ± 28
ppb) were found compared to the levels in subjects with
demonstrated Eos, although these differences did not
reach significance (Figure 3C-D).
Thus, inverse relationships were found between both
CC16 and nNO levels and MC occurrence with the
same tendency of inverse relationships and Eos
occurrence.
Discussion
In this study, we observed new relations between nasal
CC16, nNO and MC (one of the effector cells in allergic
inflammation). The levels of CC16 and nNO correlated
significantly. The levels of both CC16 and nNO correlated
inversely to the occurrence of MC, but the differences
between the lower levels of the two biomarkers in subjects
with demonstrable Eos compared to the levels in subjects
with no demonstrable Eos did not reach significance.
Our results of CC16 levels in relation to MC and Eos
are in accordance with results in studies of the lower
airways. Thus, an inverse correlation was found between
Clara cell numbers and mast cell numbers in the small
airways [18], and a negative correlation between the
CC16 levels and Eos numbers in induced sputum was
found in atopic asthmatics [19].
However, our result of nNO levels and the occurrence
of Eos in the nasal mucosa is not in accordance with
results in asthma studies, where eNO is supposed to
reflect eosinophilic inflammation [20-22]. Relations
between eNO levels and MC findings in the lower air-
ways have to our knowledge not been analyzed.
We have no unequivocal explanations to our observa-
tions. Undoubtedly, inflammatory events in allergic
inflammation are very complex. However, the quality of
airway protection of both CC16 and nNO as reported in
previous studies is of interest. Thus, CC16 is regarded
Table 1 Results of the analyzed parameters in the allergy sub-groups and the control group








Combined scores of: rhinitis symptoms 2.3 ± 2.8 0.7 ± 1.5 0.4 ± 1.1 a/c p = 0.06
bronchial symptoms 0.6 ± 1.3 0.0 0.0 n.s.
Levels of:
CC16 (OD) 15 ± 9 18 ± 12 11 ± 9 n.s.
nNO (ppb) 70 ± 34 63 ± 30 79 ± 33 n.s.
eNO (ppb) 38 ± 41 13 ± 8 13 ± 5 a/b p = 0.06
a/c p = 0.05
Number of subjects:
MCpos /MCneg 7/6 2/3 0/7 (a+b)/c p = 0.03
Eospos /Eosneg 9/4 2/3 2/4 n.s.
Symptom scores, levels of CC16, nNO and eNO and the number of subjects with/without demonstrable metachromatic cells (MCpos/MCneg) and eosinophils
(Eospos/Eosneg) in the allergy sub-groups and the control group. OD: optical density.
Figure 1 A typical western blot of expression level of CC16 in nasal lavage fluid from 4 subjects with persistent allergic rhinitis, 3
subjects with intermittent allergic rhinitis and 3 controls. 40 μg total proteins were analyzed from each subjects.
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to have anti-inflammatory effects by inhibition of PLA2
activity on arachidonic acid, reducing the availability of
the pro-inflammatory agents such as prostaglandins and
leukotriens and the chemotaxis of various inflammatory
cells [2]. It is suggested that nNO is involved in many
processes with regulatory, protective, defensive and also
deleterious effects [23]. The protective function, how-
ever, is regarded to be of importance, as the high con-
centrations in the upper airways are supposed to have a
direct inhibitory effect on the growth of pathogens and
thus enhance the local host defense against microbial
infections [10]. Regarding the lower airways, orally
exhaled NO is considered a biomarker of inflammation,
particularly in allergic asthma [20]. Interestingly, two
recent in vitro studies of the effect of NO donors and
NO synthase inhibitors on antigen induced contractile
responses and pro-inflammatory mediator release in
peripheral lung tissue, support the belief that NO has a
protective anti-inflammatory effect also in lung parench-
yma [24,25]. In a review of in vivo and in vitro studies
of NO and the regulation of mast cell activation, the
conclusion was that the protective anti-inflammatory
role of NO was predominant over pro-inflammatory
effects, due to the inhibitory actions of NO on mast cell
degranulation with decreased mediator release and
expression of cytokines [26].
Our observations are in accordance with the concept
of the anti-inflammatory roles of CC16 and nNO, as the
inverse relationships between the levels of the biomarker
and the occurrence of the effector cells might be
explained by suppressive effects on recruitment of these
cells. However, no analyses of mediators or cytokines
related to MC or Eos recruitment were included in our
study, why further studies are necessary to clarify the
mechanisms behind the observations. Likewise, the cor-
relation between the levels of CC16 and nNO has to
our knowledge not been reported before, and this obser-
vation also needs further analyses to be explained.
In the analyses of CC16 and nNO levels in the allergy
sub-groups and the control group no differences were
found between the groups. This failure of CC16 to dis-
cern allergic subjects is in disagreement with the results
from the other studies of CC16 in NLF [7-9], where sig-
nificantly lower CC16 levels were found in subjects with
current intermittent allergic rhinitis compared to
healthy controls. The different outcomes might be due
to a more modest exposure to perennial allergens com-
pared to allergen exposures during pollen seasons, a
notion supported by the low score values of nasal symp-
toms in our participants. The different results might
also, at least in part, be explained by the methods used
for analysis of the CC16 levels, which was Western blot
in our study and ELISA in the studies referred to above
[7-9].
The failure of nNO to discern allergic rhinitis groups
from controls is, however, in agreement with other
Figure 2 Correlation between CC16 and nNO levels. Correlation between the CC16 and nNO levels in subjects with allergic rhinitis (n = 18; r2
= 0.37; p = 0.02).
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studies [27-29] including the one using the same sub-
traction method for nNO calculation [30]. In contrast,
measurement of eNO levels is considered to be a useful
tool in diagnosis and management of asthma [20,21].
Interestingly, eNO measurements in our study discerned
the persistent allergy group with current allergen expo-
sure, even though very low bronchial symptom scores
were reported.
A drawback of our study is the low numbers of parti-
cipants, which was due to the use of a cohort designed
for longitudinal follow-ups not permitting substitution
of subjects excluded for various reasons. Furthermore,
the impact of CC16 and nNO on rhinitis symptoms
could not be evaluated, as the score values were too low
for permitting any tenable conclusion. Although we
regard our results as pilot observations, we consider
them to be relevant, as all analyses were performed
according to validated methods.
In order to avoid impact on nNO results due to a
reduced contribution from the paranasal sinuses we
found it to be an advantage to perform the examinations
of the subjects being in an optimal health condition with
no airway infections. No subject suffered from sinusitis
symptoms. Congestion of the nasal mucosa was
observed in three individuals with persistent allergy, but
their nNO values were above or slightly below to the
mean value of the sub-group. Thus, occlusion of the
sinus ostiae was not suspected in any of the subjects.
Conclusions
Although CC16 in NLF and nNO were found not to be
applicable biomarkers of current allergy in groups of
Figure 3 Levels of CC16 and nNO in relation to occurrences of effector cells in allergic inflammation. Levels of CC16 and nNO in the two
groups of subjects with allergic rhinitis and the control group in relation to the occurrence of metachromatic cells (A, B) and eosinophils (C, D).
PAR: persistent allergic rhinitis; IAR: intermittent allergic rhinitis. MCpos and MCneg: subjects with and without demonstrable metachromatic cells;
Eospos and Eosneg: subjects with and without demonstrable eosinophils.
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subjects with very mild rhinitis symptoms or in groups
during a free interval of allergen exposure, new details
have been observed supporting the concept of airway
protection in allergic rhinitis. Thus, the correlation
between nasal CC16 and nNO levels and the inverse
relationships between these biomarkers and the occur-
rence of MC in allergic rhinitis are results, which may
indicate protective properties of both CC16 and nNO by
suppression of cell recruitment in upper airway
inflammation.
As the results are pilot observations, further studies
are needed to clarify the mechanisms behind the obser-
vations and to analyze the impact of the two biomarkers
on rhinitis symptoms.
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